<SEC-DOCUMENT>0001013762-25-004387.txt : 20250328
<SEC-HEADER>0001013762-25-004387.hdr.sgml : 20250328
<ACCEPTANCE-DATETIME>20250328214723
ACCESSION NUMBER:		0001013762-25-004387
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250328
DATE AS OF CHANGE:		20250328

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PMGC Holdings Inc.
		CENTRAL INDEX KEY:			0001840563
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				851399981
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94408
		FILM NUMBER:		25788493

	BUSINESS ADDRESS:	
		STREET 1:		120 NEWPORT CENTER DRIVE
		STREET 2:		STE 250
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
		BUSINESS PHONE:		888-445-4886

	MAIL ADDRESS:	
		STREET 1:		120 NEWPORT CENTER DRIVE
		STREET 2:		STE 250
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Elevai Labs Inc.
		DATE OF NAME CHANGE:	20211207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Reactive Medical Labs Inc.
		DATE OF NAME CHANGE:	20210114

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Braeden Lichti
		CENTRAL INDEX KEY:			0001982476
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D

	MAIL ADDRESS:	
		STREET 1:		650 GEORGIA ST #3200
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6B4P7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lichti Braeden
		DATE OF NAME CHANGE:	20230621
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Braeden Lichti -->
          <cik>0001982476</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Series B Preferred Stock, par value $0.0001 per share</securitiesClassTitle>
      <dateOfEvent>03/26/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001840563</issuerCIK>
        <issuerCUSIP>28622K302</issuerCUSIP>
        <issuerName>PMGC Holdings Inc.</issuerName>
        <address>
          <com:street1>120 Newport Center Drive</com:street1>
          <com:street2>Ste. 249</com:street2>
          <com:city>Newport Beach</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92660</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Ross D. Carmel, Esq.</personName>
          <personPhoneNum>(212) 658-0458</personPhoneNum>
          <personAddress>
            <com:street1>Sichenzia Ross Ference Carmel LLP</com:street1>
            <com:street2>1185 Avenue of the Americas, 31st Floor</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10036</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001982476</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Braeden Lichti</reportingPersonName>
        <fundType>AF</fundType>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>Z4</citizenshipOrOrganization>
        <soleVotingPower>3336437.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>3336437.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>3336437.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>52.35</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>Mr. Lichti owns non-trading, non-convertible Series B preferred stock of PMGC Holdings, Inc. (the "Series B Preferred Stock") through Northstrive Companies Inc. ("Northstrive"), a company wholly owned by Mr. Lichti. as a signing bonus pursuant to the Second Amended and Restated Consulting Agreement between the Issuer and Northstrive, as amended. Holders of the Series B Preferred Stock have no conversion rights and no rights to dividends, unless the board of directors of the Issuer determines in its sole discretion to issue dividend payments to such holders. The Series B Preferred Stock also have no liquidation preference over any other class or series of capital stock of the Issuer. Each share of Series B Preferred Stock has one (1) vote per share on all matters. Mr. Lichti owns 52.35% of 6,372,874 shares of the Issuer's Series B Preferred Stock issued and outstanding as of March 26, 2025.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Series B Preferred Stock, par value $0.0001 per share</securityTitle>
        <issuerName>PMGC Holdings Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>120 Newport Center Drive</com:street1>
          <com:street2>Ste. 249</com:street2>
          <com:city>Newport Beach</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92660</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>Braeden Lichti (the "Reporting Person" or "Mr. Lichti")</filingPersonName>
        <principalBusinessAddress>c/o PMGC Holdings Inc., 120 Newport Center Drive, Ste. 249, Newport Beach, CA</principalBusinessAddress>
        <principalJob>The principal occupation of the Reporting Person is Chief Executive Officer of BWL Investments Ltd and NorthStrive Companies Inc., located at 620 Newport Center Drive Suite 1100, Newport Beach, California, 92660. Mr. Lichti serves as Chairman of the Board of Directors of PMGC Holdings Inc. and as Chairman of the Board of Directors of Hydromer, Inc., located at 4715 Corporate Dr NW Suite 200, Concord, NC 28027. These positions are held through a management consulting agreement with his company, NorthStrive Companies Inc. Mr. Lichti is also a non-employee director of Qualigen Therapeutics, Inc. located at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.</principalJob>
        <hasBeenConvicted>No.</hasBeenConvicted>
        <convictionDescription>No.</convictionDescription>
        <citizenship>Canada.</citizenship>
      </item2>
      <item3>
        <fundsSource>PMGC Holdings Inc. (the "Issuer") entered into a consulting agreement with Northstrive Companies Inc., a California corporation ("Northstrive") owned and managed by Braeden Lichti effective January 4, 2022 and amended on May 1, 2023. On October 25, 2024, the Issuer entered into the Second Amended and Restated Consulting Agreement with Northstrive (the "Second Amended Northstrive Companies Consulting Agreement") which stipulated the Issuer's issuance of Series B Preferred Stock to Northstrive as a sign on bonus, subject to shareholder approval. On March 26, 2025, at a special meeting of the Issuer's shareholders (the "Shareholders"), the Shareholders approved the issuance of 3,336,437 shares of non-trading, non-convertible Series B Preferred Stock under the Second Amended Northstrive Companies Consulting Agreement.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>The Reporting Person holds the Series B Preferred Stock of the Issuer for investment purposes. The Reporting Person may, from time to time, acquire additional shares of Series B Preferred Stock, and/or retain and/or sell all or a portion of the shares of Series B Preferred Stock held by the Reporting Person in the open market or in privately negotiated transactions, and/or may distribute the Series B Preferred Stock held by the Reporting Person to other entities. Any actions the Reporting Person might undertake will be dependent upon the Reporting Person's review of numerous factors, including, among other things, the price levels of the Series B Preferred Stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects, the relative attractiveness of alternative business and investment opportunities, investor's need for liquidity, and other future developments. Any future acquisitions of Series B Preferred Stock by the Reporting Person will be subject to the Company's policies, including its insider trading policy, as applicable. Except as set forth above, the Reporting Person has no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>Mr. Lichti owns 3,336,437 shares of Series B Preferred Stock through Northstrive Companies Inc., a company wholly owned by Braeden Lichti. Holders of the Series B Preferred Stock have no conversion rights and no rights to dividends, unless the board of directors of the Issuer determines in its sole discretion to issue dividend payments to such holders. The Series B Preferred Stock also have no liquidation preference over any other class or series of capital stock of the Issuer. Each share of Series B Preferred Stock has one (1) vote per share on all matters. Mr. Lichti owns 52.35% of the Issuer's 6,372,874 issued and outstanding shares of Series B Preferred Stock as of March 26, 2025.</percentageOfClassSecurities>
        <numberOfShares>Mr. Lichti has the sole power to vote and to dispose of the total amount of shares of Series B Preferred Stock held by Mr. Lichti and the legal entity owned and controlled by Mr. Lichti as described in Item 5(a) above.</numberOfShares>
        <transactionDesc>See Item 3 above.</transactionDesc>
        <listOfShareholders>Not applicable.</listOfShareholders>
        <date5PercentOwnership>Not applicable.</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>See Item 3 above.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>Not applicable.</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Braeden Lichti</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Braeden Lichti</signature>
          <title>Braeden Lichti, Self</title>
          <date>03/28/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
